CRDL Cardiol Therapeutics Earnings per share growth rate in current year

Cardiol Therapeutics (CRDL) is developing an innovative cannabidiol-based therapy for pericarditis. However, global instability and sanctions are complicating overseas testing and patent protection, which is reflected in the annual earnings per share growth profile on the GURU.Markets terminal, where -8.60 records a new level. Current revenues remain unpredictable, as the company's financial success relies entirely on the results of clinical trials.
Financial and market metric breakdowns for Cardiol (CRDL)

For the cardiology biotech Cardiol Therapeutics (CRDL), earnings per share dynamics serve as a key indicator of operational efficiency. This metric calculates the percentage change in annual net income, reflecting the growth rate of returns per ordinary share. By analyzing the percentage deviation of EPS from the previous year, an investor can discern the actual acceleration of the business. For a company with no debt, this indicator confirms the quality of capital management. Steady growth of this metric verifies the success of clinical trials.